Navigation Links
Avanafil Data Presented at the European Society of Sexual Medicine Meeting
Date:12/5/2011

tudied for the treatment of erectile dysfunction, with an FDA action date of April 29, 2012.  For more information about the company, please visit www.vivus.com

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," predict," "opportunity" and "should," among others.  There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.  These factors include, but are not limited to, the response from the United States Food and Drug Administration, or FDA, to our resubmission of the New Drug Application, or NDA, for Qnexa for the treatment of obesity, including weight loss and maintenance of weight loss, recommended for obese patients (BMI ≥30 kg/m2), or overweight patients (BMI ≥27 kg/m2) with weight-related co-morbidities such as hypertension, type 2 diabetes, dyslipidemia, or central adiposity (abdominal obesity), with a contraindication that excludes the use of Qnexa by women of child-bearing potential; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the reliability of the electronic medical claims healthcare databases used in the FORTRESS study; the FDA's interpretation of and agreement with the information VIVUS submitted relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study (OB-305) and Sleep Apnea study (OB-204); that we may be required to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; our respo
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting
2. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
3. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
4. Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting
5. Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
6. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
7. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
8. New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting
9. New Data on Vimpat® (lacosamide) C-V to Be Presented at the 65th Annual Meeting of the American Epilepsy Society
10. Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium
11. XEOMIN® (incobotulinumtoxinA) Data to be Presented at the 72nd Annual Assembly of the American Academy of Physical Medicine and Rehabilitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Based on ... market, Frost & Sullivan recognizes Ventana Medical Systems, ... with the 2014 North American Frost & Sullivan ... quality practices along with a focus on innovation ... global leader in tissue-based cancer diagnostic solutions for ...
(Date:9/30/2014)... YORK , Sept. 30, 2014  Proteomics ... according to a new report from Kalorama Information.  The ... deals had occurred in proteomics in the past ... IPOs, to agreements between private proteomic companies and ... companies with novel proteomics innovator companies.  Kalorama observed ...
(Date:9/30/2014)... Sept. 30, 2014   Decision Resources Group ... data, anemic chronic kidney disease non-dialysis (CKD-ND) patients ... (ESA) medication. In addition, one-year persistency is similar ... Other key findings from the report entitled ... of Erythropoiesis Stimulating Agents in Late Stage Chronic ...
Breaking Medicine Technology:Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. 30, 2014 ... put the brakes on motherhood. And for many young women, ... new research suggests. Women in their early 20s appear ... tough economic times. But, according to the new study, that ... 40s and beyond. The findings suggest that higher unemployment ...
(Date:9/30/2014)... "brain tsunamis" in injured patients without opening the ... thanks to pioneering research at the University of ... led by Jed Hartings, PhD, research associate professor ... College of Medicine, has shown that spreading depolarizationselectrical ... tsunami wavescan be measured by the placement of ...
(Date:9/30/2014)... 2014 (HealthDay News) -- Sleep apnea is a potential health ... to a possible culprit behind the disorder: a "fat" tongue. ... deposits are increased in the tongue of obese patients with ... of the Sleep Center at the University of Pennsylvania Medical ... which will publish the findings Oct. 1. Sleep apnea ...
(Date:9/30/2014)... stranger to the children of Tanzania. What is rare ... services, including reliable diagnosis and evidence-based treatments. There is ... in Swahili, a major language of the region. In ... and the University of Georgia (UGA) describe a culturally ... in the country and found to be effective for ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling costs ... treat Medicare patients has had no meaningful impact on ... in the Journal of Clinical Oncology published ... chemotherapy to treat colorectal and lung cancers, and did ... those drugs following the implementation of the recent Medicare ...
Breaking Medicine News(10 mins):Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 3Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Could a 'Fat Tongue' Be a Factor in Sleep Apnea? 2Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2
... food products. According to a team of University of ... on its viewers, especially university students. , "The transition ... a time for taking on many negative health behaviors ... in physical activity and fruit and vegetable consumption," said ...
... common vaginal infection may make women more susceptible to contracting ... at Chapel Hill School of Public Health researchers have found. ... more than 30,700 women from around the world, showed that ... vaginosis in women of reproductive age were more likely ...
... standardization across ... savings, IRVINE, Calif., July 31 Masimo, ... that Aurora Health Care has completed a system-wide,conversion ... health,care provider with 13 hospitals and more than ...
... support nonprofits in Portland and Seattle that improve health ... ... 31 The Regence Foundation today,announced three grants totaling $195,000 for ... Regence,Foundation is the corporate foundation of The Regence Group and was ...
... and health systems,expert Ann Lion Coleman will join ... project in August 2008. Health Systems 20/20 is ... to strengthen health,systems by using an integrated approach ... to further the use of,life-saving priority health services., ...
... July 31 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: ... Western,healthcare products and services in the People,s Republic ... its fiscal 2009 first quarter,financial results on Thursday, ... host a conference call at 8:00 am ET ...
Cached Medicine News:Health News:Watching too much TV is causing some university students to pack on the pounds 2Health News:UNC study: Common vaginal infection may increase risk of HIV infection 2Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 2Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 3Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 4Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 5Health News:Regence Foundation Announces Three Grants Totaling $195,000 2Health News:Ann Lion Coleman Joins Abt Associates to Direct USAID Health Systems 20/20 Project 2Health News:Chindex International to Report Fiscal 2009 First Quarter Financial Results 2Health News:Chindex International to Report Fiscal 2009 First Quarter Financial Results 3
... , Standby: A standby switch maintains power to ... 1 s (1 pulse/s) , Tetanus: 100 ... s) , Output Current: Adjustable from 0-70 mA ... (200-us duration) , Indicators: Battery LED (green) indicates ...
... A range of easy to use ... RDG nerve locator, peripheral nerve stimulator, and ... insulating pole, plastic hub, and pencil point ... an inexpensive, practical and easy to use ...
Based on the original MS-1 design the new MS-1B includes low battery detection, FET based output circuitry and enhanced battery compartment....
... for the delivery and monitoring of inhaled ... is a fully integrated, innovative instrument used ... therapy. The INOvent delivery system works in ... machine) to deliver a constant concentration of ...
Medicine Products: